NCT01025934
Completed
Phase 4
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Overview
- Phase
- Phase 4
- Intervention
- Bevacizumab
- Conditions
- Proliferative Diabetic Retinopathy
- Sponsor
- University of Campania "Luigi Vanvitelli"
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •vitreous haemorrhage
- •tractional retinal detachment
- •active proliferative diabetic retinopathy.
Exclusion Criteria
- •neovascular glaucoma
- •combined traction and rhegmatogenous RD
Arms & Interventions
7 days
Intervention: Bevacizumab
20 days
Intervention: Bevacizumab
sham
Intervention: sham
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of PrematurityRetinopathy of PrematurityNCT00622726The University of Texas Health Science Center, Houston150
Completed
Phase 3
Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic RetinopathyTractional Retinal Detachment Secondary to Proliferative Diabetic RetinopathyNCT01976923J. Fernando Arevalo, MD FACS224
Completed
Phase 3
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)Age Related Macular DegenerationNCT01327222IRCCS San Raffaele20
Unknown
Not Applicable
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50
Completed
Phase 1
Preoperative Bevacizumab for Vitreous HemorrhageDiabetic RetinopathyVitreous HemorrhageNCT00596297University of Sao Paulo16